

The Dual Role of Cytokines in Immunity: Balancing Pro-Inflammatory and Anti-Inflammatory Responses

Abura Geoffrey

Department of Nursing Kampala International University Uganda

Email: geoffrey.abura@studwc.kiu.ac.ug

ABSTRACT

Cytokines are essential mediators in immune regulation, balancing pro-inflammatory and anti-inflammatory responses to maintain homeostasis and combat infections. Pro-inflammatory cytokines, including TNF- α , IL-6, and IFN- γ , initiate and sustain immune activation by enhancing cellular recruitment and promoting antimicrobial activity. Conversely, anti-inflammatory cytokines such as IL-10 and TGF- β mitigate excessive inflammation, preventing tissue damage and fostering immune tolerance. This duality underscores the complex interplay between these cytokine categories, which is crucial for immune stability. Disruptions in this balance contribute to pathological conditions, including cytokine storm syndromes, autoimmune diseases, and chronic infections. Recent advances highlight therapeutic strategies targeting cytokine networks, including TNF- α inhibitors and IL-10 enhancement therapies, which aim to restore immune equilibrium. Future approaches focusing on modulating cytokine signaling pathways and cell-based therapies promise innovative solutions to immune-related disorders. This review explores the mechanisms, clinical implications, and therapeutic potential of cytokines in balancing immunity, emphasizing their significance in health and disease.

Keywords: Cytokines, Immune Regulation, Pro-Inflammatory, Anti-Inflammatory, Therapeutics

INTRODUCTION

Cytokines are small signaling proteins essential for intercellular communication in immune responses [1]. They play a pivotal role in orchestrating both innate and adaptive immunity by mediating pro-inflammatory and anti-inflammatory actions [2]. This duality is vital for maintaining immune homeostasis and responding to infections, injuries, and other stressors [3,4]. Cytokines act as molecular messengers, binding to specific receptors on target cells to initiate cascades that regulate immune cell proliferation, differentiation, and activity [5]. Their production is tightly controlled and often localized, ensuring that immune responses are appropriate to the context [4].

Pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF- α), interleukin-1 beta (IL-1 β), and interleukin-6 (IL-6), are rapidly released during infections or tissue damage [6]. They recruit immune cells to the site of injury and enhance antimicrobial

defenses. Conversely, anti-inflammatory cytokines, including interleukin-10 (IL-10) and transforming growth factor-beta (TGF- β), function to resolve inflammation and promote tissue repair [7]. This balance between pro-inflammatory and anti-inflammatory signals is critical for preventing collateral damage to host tissues while effectively neutralizing threats [8].

An imbalance in cytokine signaling can lead to pathological conditions. Overactive pro-inflammatory responses can result in chronic inflammation and tissue damage, as seen in autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease [9]. On the other hand, excessive anti-inflammatory signaling may suppress immune responses, rendering the host vulnerable to infections and impairing cancer surveillance [10]. Emerging evidence also implicates cytokine dysregulation in conditions such as metabolic

disorders, neuroinflammation, and aging-associated immune decline [11].

This review aims to delve into the mechanisms by which cytokines regulate immune functions, highlighting their dual roles in inflammation. It will explore how cytokines contribute to immune homeostasis, the consequences of their dysregulation, and the therapeutic opportunities they present for managing immune-mediated diseases. By understanding the intricate interplay of cytokine signaling, we can better appreciate their central role in health and disease.

Pro-Inflammatory Cytokines: Catalysts of Immune Activation

Key Pro-Inflammatory Cytokines

Pro-inflammatory cytokines are critical mediators of immune activation, serving as the first responders to infection, injury, or other disturbances [12]. These signaling molecules, including tumor necrosis factor- α (TNF- α), interleukin-1 beta (IL-1 β), interleukin-6 (IL-6), and interferon-gamma (IFN- γ), orchestrate the recruitment and activation of immune cells, amplifying the inflammatory response. Produced predominantly by macrophages, dendritic cells, and T-helper 1 (Th1) cells, these cytokines play essential roles in both local and systemic immunity [13,14].

Tumor Necrosis Factor-Alpha (TNF- α)

TNF- α is a master regulator of inflammation, with its primary function being the recruitment of immune cells to the site of injury or infection [15]. It activates endothelial cells to express adhesion molecules, increasing vascular permeability and facilitating leukocyte extravasation. TNF- α also stimulates the production of other pro-inflammatory cytokines, creating a positive feedback loop that sustains inflammation [16]. While its role is vital in host defense, dysregulated TNF- α activity is associated with chronic inflammatory conditions such as rheumatoid arthritis and psoriasis [17].

Interleukin-1 Beta (IL-1 β)

IL-1 β is another key pro-inflammatory cytokine, primarily produced by activated macrophages through inflammasome signaling pathways [18]. It contributes to fever, a hallmark of systemic inflammation, and enhances the expression of adhesion molecules and chemokines to attract immune cells. IL-1 β also modulates adaptive immunity by influencing the differentiation of Th17 cells, thereby linking innate and adaptive responses. Aberrant IL-1 β activity is implicated in autoinflammatory syndromes and other chronic diseases [19].

Interleukin-6 (IL-6)

IL-6 exhibits a unique duality, functioning as both a pro-inflammatory and anti-inflammatory mediator depending on the context. During acute-phase responses, IL-6 promotes the production of C-reactive protein (CRP) and other inflammatory markers [20]. It also influences the differentiation of T cells into Th17 or regulatory T cells (Tregs), highlighting its complex role in immune modulation. Persistent IL-6 signaling, however, is associated with diseases such as rheumatoid arthritis, systemic lupus erythematosus, and certain cancers [21].

Interferon-Gamma (IFN- γ)

IFN- γ , predominantly produced by Th1 cells and natural killer (NK) cells, plays a pivotal role in activating macrophages and enhancing their antimicrobial capabilities [22]. It upregulates the expression of major histocompatibility complex (MHC) molecules, thereby improving antigen presentation and T-cell activation. IFN- γ also suppresses Th2-mediated responses, ensuring an appropriate immune balance. However, excessive IFN- γ activity can contribute to autoimmune diseases, including multiple sclerosis and type 1 diabetes [23]. Pro-inflammatory cytokines are indispensable for mounting effective immune responses. Their precise regulation ensures pathogen clearance and tissue repair while preventing excessive inflammation that could harm the host. Understanding their roles and interactions provides insights into potential therapeutic interventions for inflammatory and autoimmune diseases [24].

Mechanisms of Action and Pathological Implications

Mechanisms of Action

Pro-inflammatory cytokines exert their effects through the activation of key signaling pathways, primarily the nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) and Janus kinase-signal transducer and activator of transcription (JAK-STAT) cascades [25]. The NF- κ B pathway is rapidly triggered upon recognition of pathogens or tissue damage, leading to the transcription of genes encoding inflammatory mediators, chemokines, and adhesion molecules [26]. This pathway amplifies the inflammatory response by recruiting and activating immune cells at the site of insult. Similarly, the JAK-STAT pathway mediates cytokine receptor signaling, resulting in the activation of genes essential for immune cell differentiation, proliferation, and effector functions [27]. Together, these pathways ensure a robust and coordinated immune response to eliminate threats and initiate repair mechanisms.

Pathological Implications

Although pro-inflammatory cytokines are indispensable for host defense, their dysregulation can lead to severe pathological consequences [28]. Excessive production of these cytokines can result in a "cytokine storm," characterized by an uncontrolled and widespread inflammatory response. This phenomenon is observed in conditions such as sepsis, severe COVID-19, and certain viral infections, often leading to multi-organ failure. Chronic elevation of pro-inflammatory cytokines is a hallmark of autoimmune diseases like rheumatoid arthritis, where sustained inflammation causes tissue damage and functional impairment. Additionally, persistent cytokine-mediated inflammation is implicated in metabolic disorders, neurodegenerative diseases, and cancer progression [26]. Understanding these pathological mechanisms highlights the importance of therapeutic strategies aimed at modulating cytokine activity to restore immune homeostasis and prevent disease progression.

Anti-Inflammatory Cytokines: Guardians of Immune Regulation

Key Anti-Inflammatory Cytokines

Anti-inflammatory cytokines, including interleukin-10 (IL-10), transforming growth factor-beta (TGF- β), and interleukin-4 (IL-4), are vital in modulating immune responses and maintaining tissue integrity [29]. These cytokines mitigate excessive inflammation, promote resolution, and facilitate repair processes, ensuring immune homeostasis.

Interleukin-10 (IL-10)

IL-10 is a key anti-inflammatory mediator produced by regulatory T cells (Tregs), macrophages, and B cells [30]. It suppresses the production of pro-inflammatory cytokines by inhibiting NF- κ B activation and enhancing the expression of inhibitory molecules. IL-10 also regulates antigen-presenting cells, reducing their ability to stimulate effector T cells and thereby curbing excessive immune activation [31]. Its role is particularly significant in preventing autoimmune reactions and promoting tolerance.

Transforming Growth Factor-Beta (TGF- β)

TGF- β is a multifunctional cytokine involved in immune regulation and tissue homeostasis [32]. It promotes the differentiation of naive T cells into regulatory T cells while inhibiting the activation and proliferation of pro-inflammatory Th1 and Th17 cells. TGF- β also plays a role in wound healing by stimulating fibroblast activity and extracellular matrix production, highlighting its dual role in immunity and tissue repair [33]. Dysregulation of TGF- β signaling can lead to pathological conditions, including fibrosis and cancer.

Interleukin-4 (IL-4)

IL-4, primarily secreted by T-helper 2 (Th2) cells, orchestrates humoral immunity by promoting B cell proliferation and antibody class switching [34]. It also induces macrophage polarization toward the anti-inflammatory M2 phenotype, which is associated with tissue repair and resolution of inflammation. By counteracting the effects of pro-inflammatory cytokines, IL-4 contributes to immune balance and protection against chronic inflammation [35].

Mechanisms of Action

Anti-inflammatory cytokines exert their effects by inhibiting inflammatory signaling pathways and promoting the resolution phase of immune responses. IL-10 downregulates pro-inflammatory cytokine expression and enhances regulatory mechanisms, while TGF- β fosters immune tolerance and tissue regeneration. These cytokines work synergistically to dampen excessive immune activation and prevent collateral tissue damage [36].

Pathological Implications

The imbalance of anti-inflammatory cytokines can lead to severe consequences. Insufficient activity of these cytokines may result in unchecked inflammation, contributing to autoimmune diseases such as multiple sclerosis and inflammatory bowel disease [37]. Conversely, excessive anti-inflammatory signaling can suppress immune surveillance, increasing susceptibility to infections and promoting tumor progression. Understanding the delicate equilibrium maintained by anti-inflammatory cytokines is essential for designing therapies that address immune dysreg [38].

The Dynamic Balance: Pro-Inflammatory vs. Anti-Inflammatory Responses

The immune system maintains homeostasis through a delicate balance between pro-inflammatory and anti-inflammatory cytokines [39]. This equilibrium is crucial for preventing both excessive inflammation, which can damage tissues, and insufficient immune responses, which may allow infections or cancer to progress [40]. Disruptions in this balance can result in conditions ranging from autoimmune diseases to chronic infections.

Feedback Mechanisms

Cytokines regulate each other's activity through feedback loops to ensure immune responses remain controlled [30]. For example, when excessive TNF- α signaling occurs, the production of the anti-inflammatory cytokine IL-10 is upregulated to suppress further inflammation. IL-6, a versatile cytokine, can display both pro-inflammatory and anti-inflammatory effects depending on the context [36]. These feedback mechanisms are vital for modulating the intensity and duration of immune responses.

Cellular Crosstalk

Immune cells coordinate their actions through intricate cytokine interactions [41]. For instance, Th1 cells produce IFN- γ to activate macrophages, enhancing the inflammatory response against pathogens. On the other hand, regulatory T cells (Tregs) secrete IL-10 to suppress excessive Th1 activation, preventing tissue damage and maintaining immune tolerance [42]. This cellular communication helps prevent either hyperinflammation or immune suppression.

Clinical Examples of Imbalance

1. Cytokine Storms: Conditions like sepsis or certain viral infections can trigger excessive cytokine release, leading to severe systemic inflammation.
2. Autoimmune Diseases: In disorders like lupus or multiple sclerosis, dysregulated cytokine signaling drives self-reactivity, attacking healthy tissues.
3. Chronic Infections: Prolonged infections can cause excessive anti-inflammatory responses, impairing the immune system's ability to clear pathogens effectively [43].

Therapeutic Implications

Understanding the balance between pro-inflammatory and anti-inflammatory cytokines has opened avenues for targeted therapies to manage inflammatory and autoimmune conditions effectively. These approaches aim to either neutralize harmful cytokines, enhance beneficial ones, or restore overall cytokine equilibrium [44].

Targeting Pro-Inflammatory Cytokines

Neutralizing excessive pro-inflammatory cytokines has proven effective in controlling autoimmune and inflammatory diseases [32]. Examples include:

TNF- α Inhibitors: Drugs like infliximab and adalimumab are widely used to treat conditions such as rheumatoid arthritis and inflammatory bowel disease, reducing inflammation and halting disease progression [45].

IL-6 Blockade: Tocilizumab, an IL-6 receptor antagonist, has shown efficacy in managing cytokine storm syndromes, such as those seen in severe COVID-19 cases and systemic inflammatory disorders [46].

Enhancing Anti-Inflammatory Cytokines

Boosting anti-inflammatory cytokines offers a promising approach for mitigating chronic inflammation and promoting immune tolerance:

IL-10 Therapy: IL-10 is under investigation for its potential to treat chronic inflammatory diseases, including Crohn's disease and psoriasis [38].

TGF- β Modulation: Therapies targeting TGF- β aim to enhance tissue repair and regulate immune responses, particularly in fibrotic and autoimmune diseases [35].

Balancing Cytokine Responses

Emerging strategies emphasize restoring a balanced cytokine network instead of targeting specific cytokines [47]:

JAK-STAT Pathway Modulators: These drugs adjust cytokine signaling to maintain homeostasis, offering broader therapeutic potential [25].

Cell-Based Therapies: Techniques using regulatory T cells (Tregs) or engineered cells deliver cytokines in a controlled manner, promoting precise immune modulation [20].

CONCLUSION

Cytokines are essential mediators of immunity, orchestrating both inflammatory and anti-inflammatory responses. Their balanced regulation ensures immune homeostasis and effective defense against infections and injuries. Dysregulation, however, contributes to the pathogenesis of immune-related diseases. Advances in understanding cytokine

signaling and interplay have provided critical insights for developing targeted therapies. Ongoing research holds promise for refining strategies to manipulate cytokine networks, offering improved clinical outcomes and novel treatments for inflammatory and autoimmune conditions.

REFERENCES

1. Altan-Bonnet G, Mukherjee R. Cytokine-mediated communication: a quantitative appraisal of immune complexity. *Nat Rev Immunol.* 2019 Apr;19(4):205-217. doi: 10.1038/s41577-019-0131-x. PMID: 30770905; PMCID: PMC68126146.
2. Sam-Yellowe, T.Y. (2021). Cytokines. In: *Immunology: Overview and Laboratory Manual*. Springer, Cham. https://doi.org/10.1007/978-3-030-64686-8_14
3. Schirmer, B., Neumann, D. (2019). Cytokines. In: Parnham, M., Nijkamp, F., Rossi, A. (eds) *Nijkamp and Parnham's Principles of Immunopharmacology*. Springer, Cham. https://doi.org/10.1007/978-3-030-10811-3_6
4. Barnes BJ and Somerville CC (2020) Modulating Cytokine Production via Select Packaging and Secretion from Extracellular Vesicles. *Front. Immunol.* 11:1040. doi: 10.3389/fimmu.2020.01040
5. Liu Yang, Jun R. Huh, Gloria B. Choi. One messenger shared by two systems: How cytokines directly modulate neurons,

- Current Opinion in Neurobiology, 2023; 80, 102708.
<https://doi.org/10.1016/j.conb.2023.102708>.
6. John E. Niederhuber, James O. Armitage, Michael B. Kastan, James H. Doroshow, Joel E. Tepper, Abeloff's Clinical Oncology (Sixth Edition), Elsevier, 2020, 24-46.e12.
<https://doi.org/10.1016/B978-0-323-47674-4.00002-5>.
7. Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol. 2009 Aug;9(4):447-53. doi: 10.1016/j.coph.2009.04.008. Epub 2009 May 29. PMID: 19481975; PMCID: PMC2755239.
8. Steen EH, Wang X, Balaji S, Butte MJ, Bollyky PL, Keswani SG. The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis. Adv Wound Care (New Rochelle). 2020 Apr 1;9(4):184-198. doi: 10.1089/wound.2019.1032. Epub 2020 Feb 7. PMID: 32117582; PMCID: PMC7047112.
9. Al-Qahtani AA, Alhamlan FS, Al-Qahtani AA. Pro-Inflammatory and Anti-Inflammatory Interleukins in Infectious Diseases: A Comprehensive Review. *Tropical Medicine and Infectious Disease*. 2024; 9(1):13. <https://doi.org/10.3390/tropicalmed9010013>
10. Nitish Kumar Bhol, Madhabi Madhusmita Bhanjadeo, Anup Kumar Singh, Umesh Chandra Dash, Rakesh Ranjan Ojha, Sanatan Majhi, Asim K. Duttaroy, Atala Bihari Jena, The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds, *Biomedicine & Pharmacotherapy*, 2024; 178, 117177. <https://doi.org/10.1016/j.biopha.2024.117177>.
11. Eduard Batlle, Joan Massagué, Transforming Growth Factor-β Signaling in Immunity and Cancer, *Immunity*, 2019; 50 (4): 924-940. <https://doi.org/10.1016/j.immuni.2019.03.024>.
12. Al-Qahtani AA, Alhamlan FS, Al-Qahtani AA. Pro-Inflammatory and Anti-Inflammatory Interleukins in Infectious Diseases: A Comprehensive Review. *Trop Med Infect Dis*. 2024 Jan 4;9(1):13. doi: 10.3390/tropicalmed9010013. PMID: 38251210; PMCID: PMC10818686.
13. Stiel, L., Gaudet, A., Thietart, S. *et al*. Innate immune response in acute critical illness: a narrative review. *Ann. Intensive Care* 14, 137 (2024). <https://doi.org/10.1186/s13613-024-01355-6>
14. Zhang H, Dhalla NS. The Role of Pro-Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease. *International Journal of Molecular Sciences*. 2024; 25(2):1082. <https://doi.org/10.3390/ijms25021082>
15. Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH. The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics. *Int J Mol Sci*. 2021 Mar 8;22(5):2719. doi: 10.3390/ijms22052719. PMID: 33800290; PMCID: PMC7962638.
16. Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. *Crit Rev Eukaryot Gene Expr*. 2010;20(2):87-103. doi: 10.1615/critrevukargeneexpr.v20.i2.10. PMID: 21133840; PMCID: PMC3066460.
17. Chen, S., Saeed, A.F., Liu, Q. *et al*. Macrophages in immunoregulation and therapeutics. *Sig Transduct Target Ther* 8, 207 (2023). <https://doi.org/10.1038/s41392-023-01452-1>
18. Muhammad, M. (2020). Tumor Necrosis Factor Alpha: A Major Cytokine of Brain Neuroinflammation. *IntechOpen*. doi: 10.5772/intechopen.85476
19. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. *Cold Spring Harb Perspect Biol*. 2014 Sep 4;6(10):a016295. doi: 10.1101/cshperspect.a016295. PMID: 25190079; PMCID: PMC4176007.
20. Del Giudice M, Gangestad SW. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. *Brain Behav Immun*. 2018 May;70:61-75. doi: 10.1016/j.bbi.2018.02.013. Epub 2018 Mar 1. PMID: 29499302.
21. Kistner, T.M., Pedersen, B.K. & Lieberman, D.E. Interleukin 6 as an energy allocator in muscle tissue. *Nat Metab* 4, 170-179 (2022). <https://doi.org/10.1038/s42255-022-00538-4>

22. Alspach E, Lussier DM, Schreiber RD. Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. *Cold Spring Harb Perspect Biol.* 2019 Mar 1;11(3):a028480. doi: 10.1101/cshperspect.a028480. PMID: 29661791; PMCID: PMC6396335.
23. Dillon SM, Lee EJ, Bramante JM, Barker E, Wilson CC. The natural killer cell interferon-gamma response to bacteria is diminished in untreated HIV-1 infection and defects persist despite viral suppression. *J Acquir Immune Defic Syndr.* 2014 Mar 1;65(3):259-67. doi: 10.1097/01.qai.0000435603.50598.2b. PMID: 24091697; PMCID: PMC3945425.
24. Katkenov N, Mukhatayev Z, Kozhakhmetov S, Sailybayeva A, Bekbossynova M, Kushugulova A. Systematic Review on the Role of IL-6 and IL-1 β in Cardiovascular Diseases. *Journal of Cardiovascular Development and Disease.* 2024; 11(7):206. <https://doi.org/10.3390/jcdd11070206>
25. Al-Qahtani AA, Alhamlan FS, Al-Qahtani AA. Pro-Inflammatory and Anti-Inflammatory Interleukins in Infectious Diseases: A Comprehensive Review. *Trop Med Infect Dis.* 2024 Jan 4;9(1):13. doi: 10.3390/tropicalmed9010013. PMID: 38251210; PMCID: PMC10818686.
26. Janice K. Kiecolt-Glaser, Jean-Philippe Gouin, Liisa Hantsoo, Close relationships, inflammation, and health, *Neuroscience & Biobehavioral Reviews*, 2010; 35(1): 33-38. <https://doi.org/10.1016/j.neubiorev.2009.09.003>.
27. Kennedy, R.H., Silver, R. (2015). Neuroimmune Signaling: Cytokines and the CNS. In: Pfaff, D., Volkow, N. (eds) *Neuroscience in the 21st Century*. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6434-1_174-1
28. Hanna, A., Frangogiannis, N.G. Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure. *Cardiovasc Drugs Ther* 34, 849–863 (2020). <https://doi.org/10.1007/s10557-020-07071-0>
29. Lobo-Silva, D., Carriche, G.M., Castro, A.G. *et al.* Balancing the immune response in the brain: IL-10 and its regulation. *J Neuroinflammation* 13, 297 (2016). <https://doi.org/10.1186/s12974-016-0763-8>
30. Wenjun Ouyang, Anne O'Garra, IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation, *Immunity*, 2019; 50(4): 871-891. <https://doi.org/10.1016/j.immuni.2019.03.020>.
31. Carlini V, Noonan DM, Abdalalem E, Goletti D, Sansone C, Calabrone L and
32. Albini A (2023) The multifaceted nature of IL-10: regulation, role in immunological homeostasis and its relevance to cancer, COVID-19 and post-COVID conditions. *Front. Immunol.* 14:1161067. doi: 10.3389/fimmu.2023.1161067
33. Deng, Z., Fan, T., Xiao, C. *et al.* TGF- β signaling in health, disease and therapeutics. *Sig Transduct Target Ther* 9, 61 (2024). <https://doi.org/10.1038/s41392-024-01764-w>
34. Sanjabi S, Oh SA, Li MO. Regulation of the Immune Response by TGF- β : From Conception to Autoimmunity and Infection. *Cold Spring Harb Perspect Biol.* 2017 Jun 1;9(6):a022236. doi: 10.1101/cshperspect.a022236. PMID: 28108486; PMCID: PMC5453394.
35. Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. *Cytokine.* 2015 Sep;75(1):14–24. doi: 10.1016/j.cyto.2015.05.010. Epub 2015 Jun 1. PMID: 26044597; PMCID: PMC4532589.
36. Sahoo A, Wali S, Nurieva R. T helper 2 and T follicular helper cells: Regulation and function of interleukin-4. *Cytokine Growth Factor Rev.* 2016 Aug; 30:29–37. doi: 10.1016/j.cytogfr.2016.03.011. Epub 2016 Mar 31. PMID: 27072069; PMCID: PMC5110032.
37. Christopher E. Brightling, Dhananjay Desai, Ian D. Pavord, 93 - Cytokine-Specific Therapy in Asthma, Editor(s): N. Franklin Adkinson, Bruce S. Bochner, A. Wesley Burks, William W. Busse, Stephen T. Holgate, Robert F. Lemanske, Robyn E. O'Hehir, Middleton's Allergy (Eighth Edition),
38. W.B. Saunders, 2014, 1491-1502. <https://doi.org/10.1016/B978-0-323-08593-9.00094-2>.
39. Dinarello CA. Anti-inflammatory Agents: Present and Future. *Cell.* 2010 Mar

- 19;140(6):935-50.doi: 10.1016/j.cell.2010.02.043.PMID: 20303881; PMCID: PMC3752337.
40. Bennett JM, Reeves G, Billman GE and Sturmberg JP (2018). Inflammation–Nature’s Way to Efficiently Respond to All Types of Challenges: Implications for Understanding and Managing “the Epidemic” of Chronic Diseases. *Front. Med.* 2018; 5:316. doi: 10.3389/fmed.2018.00316
 41. Yaqubi, K., Kostev, K., Klein, I. *et al.* Inflammatory bowel disease is associated with an increase in the incidence of multiple sclerosis: a retrospective cohort study of 24,934 patients. *Eur J Med Res* **29**, 186 (2024). <https://doi.org/10.1186/s40001-024-01776-w>
 42. Khan AW, Farooq M, Hwang M-J, Haseeb M, Choi S. Autoimmune Neuroinflammatory Diseases: Role of Interleukins. *International Journal of Molecular Sciences*. 2023; 24(9):7960. <https://doi.org/10.3390/ijms24097960>
 43. Altan-Bonnet G, Mukherjee R. Cytokine-mediated communication: a quantitative appraisal of immune complexity. *Nat Rev Immunol.* 2019 Apr;19(4):205-217. doi: 10.1038/s41577-019-0131-x. PMID: 30770905; PMCID: PMC8126146.
 44. Cui, A., Huang, T., Li, S. *et al.* Dictionary of immune responses to cytokines at single-cell resolution. *Nature* **625**, 377–384 (2024). <https://doi.org/10.1038/s41586-023-06816-9>
 45. Hirad Daneshpour, Hyun Youk, Modeling cell–cell communication for immune systems across space and time, *Current Opinion in Systems Biology*, 2019; 18, 44–52. <https://doi.org/10.1016/j.coisb.2019.10.008>.
 46. West NR (2019) Coordination of Immune-Stroma Crosstalk by IL-6 Family Cytokines. *Front. Immunol.* 10:1093. doi: 10.3389/fimmu.2019.01093
 47. Adorini L. Cytokine-based immunointervention in the treatment of autoimmune diseases. *Clin Exp Immunol.* 2003 May;132(2):185-92. doi: 10.1046/j.1365-2249.2003.02144.x. PMID: 12699404; PMCID: PMC1808696.
 48. Moudgil KD, Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. *J Interferon Cytokine Res.* 2011Oct;31(10):695-703. doi: 10.1089/jir.2011.0065. Epub 2011 Sep 23. PMID: 21942420; PMCID: PMC3189547.
 49. Montazersaheb, S., Hosseiniyan Khatibi, S.M., Hejazi, M.S. *et al.* COVID-19 infection: an overview on cytokine storm and related interventions. *Viral J* **19**, 92 (2022). <https://doi.org/10.1186/s12985-022-01814-1>

CITE AS: Abura Geoffrey (2025). The Dual Role of Cytokines in Immunity: Balancing Pro-Inflammatory and Anti-Inflammatory Responses. INOSR APPLIED SCIENCES 13(1):28-34. <https://doi.org/10.59298/INOSRAS/2025/13.1.2834000>